It has been estimated that testing all women diagnosed with HGSC for a BRCA1 or BRCA2 gene mutation could reduce breast and ovarian cancer in first-degree relatives by 20% and 55%, respectively [9]. This evidence concerns the gene BRCA1 and ovarian cancer.